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Additional Sources 
Signs and Symptoms 
Gout, an inflammatory arthritis caused by elevated serum uric acid 
levels, is emerging as a significant risk factor for cardiovascular 
disease (CVD).  Recently, a nurse practitioner (NP) was caring for  a 
patient who was suffering from a particularly severe gout attack 
while being treated in the ICU for new onset Atrial Fibrillation.  The 
patient reported that he had never had an attack this severe before.  
He asked the NP if his history of gout could be related to his recent 
heart problems.  The nurse practitioner, in order to answer the 
patient’s question, spent time researching the disease process of 
gout, as well as, the possibility of association between gout and 
cardiovascular disease.  She learned that current research provides 
clear evidence that gout is a risk factor for CVD.  In the course of  her 
research, she advanced her knowledge of the pathophysiology of 
gout and the significance of gout’s risk for CVD.  Finally, utilizing this 
knowledge will help her to manage the care of patients with gout and 
cardiovascular disease. 
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Fig. 7. Direct and indirect causal pathways linking hyperuricemia, gout, 
and CVD. MSU, monosodium urate.  (Bhole & Krishnan, 2014, p. 140). 
 
Thorough research has provided knowledge about gout and its 
association with increased risk of cardiovascular disease for both 
the nurse and the patient.  After sharing what she learned, the 
nurse and the patient discussed how to decrease his risk for future 
EAIs and for CVD.  She provided education on how he can modify 
his diet, exercise, medications, etc.  Utilizing this knowledge, its 
significance and practice implications, the nurse is better prepared 
to care for future patients suffering from gout and CVD. 
Conclusion 
Additionally, there is a hereditary component to the ability of certain 
populations in renal uric handling of acid and hyperuricemia (87% for 
fractional excretion of uric acid, 60% for serum urate) (Merriman, Choi, & 
Dalbeth, 2014, p. 280).   
L. B. is a 64 year old male hospitalized in the Intensive Care Unit 
(ICU) for new onset Atrial Fibrillation.  On his second day in the 
hospital, L. B. underwent a stress test, which he ultimately failed.  
Eight hours after the stress test, L. B. developed severe pain, redness, 
and swelling in bilateral hands, wrists, feet, and ankles.  The patient 
was given Furosemide 20mg IVP, which did not alleviate the swelling 
and pain.  Finally, it was identified that he was experiencing an 
episode of acute inflammation (EAI) of gout and he was given 
Methelprednisone 60mg IVP.  This relieved the swelling and pain 
enough that he could be discharged.  Ultimately, L. B. underwent 
cardiac catheritization where he received a stent for an 80% 
occlusion to his circumflex artery.   
L. B. has a medical history of atrial fibrillation, gouty arthritis, 
hyperlipidemia, and GERD.  Surgical history reveals left knee 
replacement (2015), left rotator cuff repair (2008), right rotator cuff 
repair (2004), and right knee replacement (1997).  Current 
medications are Plavix 75mg, Sotalol 80 mg, Colchicine 0.6mg, 
Allopurinol 300mg, and Coumadin 2mg.  
A direct and indirect association between the pathophysiology 
of gout and the risk for developing CVD has been well established 
by past and current research.  Unfortunately, gout is a common 
condition.  In fact, gout is one of the most common conditions seen 
by practitioners.  Its prevalence is higher than rheumatoid arthritis 
and in some studies it’s equal to fibromyalgia and more prevalent 
than kidney disease, liver disease and prostate cancer in annual 
primary care visits in the United States (Vannucchi, 2012, p. 192).  
Therefore, as the incidence of gout increases in the population, so 
is the risk for CVD increasing.  It is imperative that practitioners 
recognize this vital association so they can be prepared to treat a 
patient’s gout and assess for CVD risk. 
Underlying Pathophysiology 
A thorough knowledge of the phases of the disease is required 
to effectively manage gout (Hardy, 2011, p. 19).  Not only must 
the NP efficiently and effectively treat the EAIs of gout, but also 
manage the chronic inflammation as well.  Furthermore, because 
of the well documented association between gout and 
cardiovascular disease, the nurse practitioner must evaluate a 
patient with the diagnosis of gout for the increased risk of CVD.  
For example, if a patient presents with acute symptoms of gout, 
there should be an automatic assessment for CVD.  The 
assessment for cardiovascular risk factors should then lead to 
patient education about the increased future risk for 
cardiovascular disease (Bhole & Krishnan, 2014, p. 141). 
Significance of Pathophysiology 
Figure 1. 
This is a picture of L.B.’s right foot and ankle shortly after discharge 
from the ICU.  This picture was provided by L. B. and permission for 
the picture to be printed was obtained from L. B. 
There are two phases of gout:  acute and chronic.  Each phase has distinct 
signs and symptoms (Perez-Ruiz, Castillo, Chinchilla, & Herrero-Beites, 2014, 
p. 194).   
 
Phase 1:  Acute gout- episodes of acute inflammation (EAI) 
 
     ●  sudden onset of symptoms 
     ●  pain – most severe in the first 12 – 24 hours 
     ●  erythema (localized redness) 
     ●  inflammation of soft tissue of articular and periarticular joint  
               structures 
     ●  most commonly affected joint is the first metatarsophalangeal  
               (MTP) joint of the lower limbs - classic podagra (the hallmark  
                symptom of gout) 
     ●  most commonly affected upper limb joint is the olecranon bursa.  
                Hands can also be affected. 
     ●  monoarticular distribution (single structure involvement) is the  
                most common.  









Fig. 3. (A) Rapid development of extended intradermal tophi in the 
fingerpads in a patient with serum urate level >12 mg/dL caused by 
chronic kidney disease and chronic heart failure on high-dose diuretics 
(Perez-Ruiz et al., 2014, p. 197). 
 
Phase 2:  Chronic gout – persistent or nonacute 
 
     ●  palpable tophi (macroscopic aggregate of monosodium urate crystals  
                [MSUCs])  
     ●  gouty arthropathy – persistent joint limitations 
     ●  chronic gouty arthritis – persistent joint swelling 
     ●  joint deformity 
     ●  oligoarticular and polyarticular distribution may occur if gout is 
                severe, persistent and untreated for an extended length of  
                time. 
     ●  increased risk for cardiovascular disease 
 
 
Pathophysiology of gout as a risk factor for cardiovascular disease   
 
Over time, this chronic form of inflammation [gout] can perceivably 
increase the risk of CVD (Bhole & Krishnan, 2014, p. 126).  There are 
several mechanisms that explain the association between gout and CVD.  
The direct pathway starts with hyperuricemia to deposition of MSU crystals 
into the synovial spaces of joints.  This results in chronic low-grade 
inflammation which promotes atherogenesis and thrombogenesis.  
Additionally, there are reports that link hyperuricemia with greater 
coronary artery calcifications (Bhole & Krishnan, 2014, p. 126).  Ultimately, 
untreated high levels of uric acid in the blood will increase the patient’s risk 
for CVD.   
The indirect pathway proves that there are shared risk factors for gout 
and CVD.  Research has shown that patients with gout also have the same 
risk factors for CVD.  These include:  male gender, age, diabetes, 
hypertension, obesity, alcohol consumption, metabolic syndrome, and 
menopause (Bhole & Krishnan, 2014, p. 139).   
As the level of urate in the blood increases, it precipitates and forms 
monosodium urate (MSU) crystals.  MSU crystals, once deposited in the 
tissues and synovial space of the joint, initiates an acute inflammatory 
response.  The inflammatory response attracts leukocytes to hte synovial 
space and phagocytize the MSU crystals.  This releases destructive 
enzymes that cause more inflammation and tissue damage.   
Pathophysiology of gout 
 
High levels of serum urate, hyperuricemia, is the main cause of gout.  
Hyperuricemia is when serum uric acid levels are greater than 7.0 mg/dL.  
Elevated serum uric acid levels can occur from two different causes:  
overproduction of hepatic urate through purine synthesis de novo and 
salvage pathways or renal under excretion of uric acid.  
